[1]王黎洲,李 兴,宋 杰,等.血管内皮生长因子基因型对介入化疗栓塞 治疗原发性肝癌预后的评估[J].介入放射学杂志,2015,(05):396-399.
　WANG Li zhou,LI Xing,SONG Jie,et al.Application of polymorphisms of vascular endothelial growth factor in evaluating the prognosis of hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment[J].journal interventional radiology,2015,(05):396-399.
点击复制

血管内皮生长因子基因型对介入化疗栓塞 治疗原发性肝癌预后的评估 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年05期
页码:
396-399
栏目:
肿瘤介入
出版日期:
2015-05-25

文章信息/Info

Title:
Application of polymorphisms of vascular endothelial growth factor in evaluating the prognosis of hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment
作者:
王黎洲;  李 兴;  宋 杰;  蒋天鹏;  吴晓萍;  周 石
Author(s):
WANG Li zhou;  LI Xing;  SONG Jie;  JIANG Tian peng;  WU Xiao ping;  ZHOU Shi
Department of Radiology， Affiliated Hospital of Guiyang Medical College， Guiyang， Guizhou Province 550004， China
关键词:
【关键词】 临床结果;  多态性;  肝癌;  血管内皮生长因子
文献标志码:
A
摘要:
【摘要】 目的 通过检测血管内皮生长因子（VEGF）的基因类型，探讨不同类型基因与原发性肝癌（HCC）患者TACE术后生存率的关系。方法 通过384孔板DNA提取试剂盒检测2007年1月到2008年1月156例经过病理确诊2个月内接受TACE治疗HCC患者的VEGF基因型并收集所有患者的临床资料，分析不同基因类型与患者预后的关系。结果 本研究共检测出VEGF 2578C/A，VEGF 1154G/A，VEGF 634C/G和VEGF 1498T/C 4种基因型，患者的5年生存率为55.47%。经多变量分析显示，肿瘤分期（TMN）、癌灶转移、VEGF 2578 AA和VEGF 1154 AA基因型是独立预后因素。肝癌TMN分期为Ⅲ至Ⅳ期将极大增加肝癌患者死亡风险（HR=3.64，95%，CI=1.67-6.79；HR=2.91，CI=1.30-6.27）。然而VEGF 2578 AA和VEGF 1154 AA基因类型患者相比野生基因类型死亡风险更高（HR=3.65，95%CI=1.35-11.13；HR=7.13， 95%CI=1.46-65.8）。结论 VEGF 2578C/A和VEGF 1154G/A基因类型与接受TACE治疗的原发性肝癌患者预后密切相关，可能对预测介入治疗HCC的预后有一定帮助。

参考文献/References:

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61: 69 90.
［2］ Wu KT, Wang CC, Lu LG, et al. Hepatocellular carcinoma: clinical study of long term survival and choice of treatment modalities［J］. World J Gastroenterol, 2013, 19: 3649 3657.
［3］ Bruix J, Sherman M. Management of hepatocellular carcinoma: an update［J］. Hepatology, 2011, 53: 1020 1022.
［4］ Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembo lization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172 patient cohort［J］. Radiology, 2010, 255: 955 965.
［5］ Sáenz López P, Vazquez F, Cozar JM, et al. VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population［J］. Hum Immunol, 2013, 74: 98 103.
［6］ Oh SY, Kwon HC, Kim SH, et al. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer［J］. BMC Cancer, 2013, 13: 43.
［7］ Sun SF, Huang DB, Cao C, et al. Polymorphism of VEGF 460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population［J］. Med Oncol, 2013, 30: 410.
［8］ 李 丁， 向 华． 血管内皮生长因子在原发性肝癌中的诊断及预后意义［J］． 介入放射学杂志， 2014， 23： 1018 1021．
［9］ Absenger G, Szkandera J, Stotz M, et al. A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in Early Stage breast cancer［J］. Mol Carcinog, 2013, 52: 96 102.
［10］ Chien MH, Liu YF, Hsin CH, et al. Impact of VEGF C gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan［J］. PLoS One, 2013, 8: e60283.
［11］ Luo T, Chen L, He P, et al.Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population［J］. Asian Pac J Cancer Prev, 2013, 14: 2433 2437.
［12］ Sa Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, et al. Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness［J］. Mol Med Rep, 2013, 8: 1242 1250.
［13］ Wu X, Xin Z, Zhang W, et al. Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity［J］. Int J Cancer, 2013, 133: 1085 1093.
［14］ Tamura T， Kuwahara A， Yamamori M， et al.VEGF 634C/G genotype is predictive of long term survival after treatment with a definitive 5 fluorouracil/cisplatin based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma［J］. Int J Med Sci, 2012, 9: 833 837.
［15］ 杨柏帅， 施裕新， 袁 敏， 等． TACE治疗既往有肝功能衰竭史肝癌患者七例［J］． 介入放射学杂志， 2014， 23： 805 808．

相似文献/References:

[1]丁 远,王黎洲,宋 杰,等.细胞色素P450酶2C19基因多态性对TIPS术后患者服用氯吡格雷效果的影响 [J].介入放射学杂志,2017,(07):588.
　DING Yuan,WANG Lizhou,SONG Jie,et al.The influence of CYP2C19 gene polymorphism on the curative effect of clopidogrel in patients after receiving TIPS[J].journal interventional radiology,2017,(05):588.

备注/Memo

备注/Memo:
（收稿日期：２０１5-０1-０9）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2015-05-19